This trial is testing whether MRI can help detect prostate cancer earlier in men who are at high risk for the disease because they have a BRCA1 or BRCA2 mutation.
- Prostate Cancer
1 Primary · 1 Secondary · Reporting Duration: 2 years (January 2016)
Awards & Highlights
1 Treatment Group
MS3TMRI / TRUS Guided Biopsy
1 of 1
60 Total Participants · 1 Treatment Group
Primary Treatment: MS3TMRI / TRUS Guided Biopsy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · Male Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the estimated size of this medical experiment's participant pool?
"Affirmative, the information available on clinicaltrials.gov implies that recruitment for this experiment is ongoing. Initially posted in January 2014, it was subsequently edited as recently as May 2022 and seeks a total of 60 individuals from 1 test site." - Anonymous Online Contributor
Can participants join this experiment currently?
"According to the clinicaltrials.gov registry, this medical study is currently seeking participants. It was initially made available on January 1st 2014 and recently revised on May 5th 2022." - Anonymous Online Contributor